IRulya Therapeutics Inc. filed a Form 8-K on October 19, 2026, to disclose an updated Corporate Presentation dated October 2026. The filing, accessible via the company’s investor relations website, details the status of the company’s lead product candidate, LAM-001, and outlines anticipated development milestones.
LAM-001 is described as a novel, once-daily, inhaled, disease-modifying formulation of rapamycin. The presentation highlights the limitations of current oral rapamycin therapies, which suffer from low and variable bioavailability and significant systemic toxicity risks, including angioedema and renal impairment. IRulya asserts that LAM-001 is designed to deliver higher drug exposure directly to the lungs while minimizing systemic exposure, offering a potentially improved safety profile.
The company is advancing LAM-001 across three Phase 2 programs targeting pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome (BOS), and sarcoidosis-associated pulmonary hypertension (SAPH). For PH-ILD, the company noted promising Phase 2a data presented at the ATS 2026 conference. A Phase 2b trial for PH-ILD is expected to initiate in mid-2026. A Phase 2 trial for BOS is ongoing, with data expected in the first quarter of 2027. A Phase 2 trial for SAPH is expected to begin in the fourth quarter of 2026.
The presentation also provides estimated addressable patient populations in the US and EU for these indications. For PH-ILD, the estimated population is approximately 200,000. For BOS, it is approximately 30,000. For SAPH, the estimated population is approximately 60,000. The company anticipates data readouts for these programs in 2027 and 2028.
